Senseonics (SENS) can be an appealing growth option for aggressive portfolios seeking exposure to innovative medical device advancements in diabetes care, specifically due to its pioneering long-term implantable sensors. However, because the company continues to navigate high operating expenses associated with direct-to-consumer marketing and commercial scaling, conservative investors often view it as a high-risk asset requiring careful monitoring of quarterly financial burn rates.